Eli Lilly Canada is recalling a batch of an injectable prescription drug used to treat low blood sugar levels which can occur in people with diabetes who are being treated with insulin.
The company is recalling the batch following a complaint that a vial of this batch of Glucagon – D239382A, expiration date May 10, 2022 – was found to be in liquid form instead of powder.
Glucagon normally comes in powder form, along with a diluting solution, and should be used immediately after mixing, according to a Health Canada release released on Saturday.
“Vials from the affected lot may not work as intended in treating patients with hypoglycemia. [low blood sugar] resulting in persistent hypoglycemia. It could also lead to other serious health consequences, such as loss of consciousness and seizures, ”the statement said.
Health Canada has warned people not to use the product in this batch, and if they have, they should call 911 immediately if there are any medical problems, such as hypoglycemia or seizures.
Insulin helps prevent blood sugar levels from rising too high, while glucagon is given as an emergency treatment when levels are too low which can lead to confusion, dizziness, seizures or loss of consciousness.